To this end, we developed MK2 shRNA constructs in 2 human HNSCC models (Cal27 and Tu167) that demonstrated reduced MK2 expression and phosphorylation (Fig. 1D) to assess MK2’s role in migratory-invasive capacity. The gene discussed is MAPKAPK2; the disease is head and neck squamous cell carcinoma.